CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
76.41
-0.62 (-0.80%)
Aug 12, 2026, 3:50 PM EDT - Market open
CG Oncology Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -224.38 | -161 | -88.04 | -48.61 | -35.44 | -12.84 |
Depreciation & Amortization | 2.96 | 1.45 | 0.03 | 0.02 | 0.02 | 0.01 |
Stock-Based Compensation | 35.33 | 26.68 | 11.4 | 1.53 | 0.68 | 1.11 |
Other Adjustments | 5.8 | -1.75 | -5.01 | -2.06 | 0.51 | 0.03 |
Change in Receivables | - | -0.32 | - | - | - | - |
Changes in Inventories | - | -0.44 | - | - | - | - |
Changes in Accounts Payable | 4.76 | -1.64 | 3.28 | 2.01 | -0.02 | 0.58 |
Changes in Accrued Expenses | 9.7 | 8.66 | 5.47 | 4.14 | 3.33 | -0.46 |
Changes in Other Operating Activities | -5.76 | -3.97 | -5.84 | -2.71 | 1.13 | -2.08 |
Operating Cash Flow | -178.47 | -132.35 | -78.71 | -45.68 | -29.8 | -13.65 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.88 | -0.13 | -0.23 | - | -0.01 | -0.1 |
Purchases of Investments | -1,321 | -1,068 | -1,046 | -517.61 | -55.34 | - |
Proceeds from Sale of Investments | 953.37 | 844.14 | 745.41 | 396.42 | - | - |
Cash Acquisitions | - | -21.97 | - | - | - | - |
Investing Cash Flow | -364.88 | -245.82 | -300.76 | -121.2 | -55.35 | -0.1 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | - | - | 15.2 |
Long-Term Debt Repaid | - | - | -0.37 | -16.29 | - | - |
Net Long-Term Debt Issued (Repaid) | - | - | -0.37 | -16.29 | - | 15.2 |
Issuance of Common Stock | 548.51 | 153.91 | 632.07 | 2.08 | 0.17 | 0.25 |
Repurchase of Common Stock | -0.19 | - | - | - | - | - |
Net Common Stock Issued (Repurchased) | 548.31 | 153.91 | 632.07 | 2.08 | 0.17 | 0.25 |
Issuance of Preferred Stock | - | - | - | 104.63 | 119.53 | - |
Net Preferred Stock Issued (Repurchased) | - | - | - | 104.63 | 119.53 | - |
Other Financing Activities | 0.05 | -0.32 | -3.42 | -3.42 | - | - |
Financing Cash Flow | 548.36 | 153.59 | 628.28 | 87 | 119.69 | 15.45 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 5.01 | -224.58 | 248.8 | -79.88 | 34.54 | 1.7 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -179.34 | -132.48 | -78.95 | -45.68 | -29.82 | -13.75 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -2879.62% | -3279.21% | -6931.26% | -22391.70% | -15611.50% | -132.76% |
Free Cash Flow Per Share | -2.18 | -1.71 | -1.26 | -10.55 | -7.97 | -3.77 |
Levered Free Cash Flow | -213.6 | -157.09 | -85.7 | -80.63 | -39.35 | -5.24 |
Unlevered Free Cash Flow | -241.84 | -186.87 | -111.96 | -51.99 | -30.81 | -14.66 |